How well does Forteo(Teriparatide) work?

FORTEO (teriparatide injection) is a recombinant human parathyroid hormone analog that stimulates new bone formation on trabecular and cortical bone surfaces by preferentially activating osteoblastic activity over osteoclastic activity, thereby increasing bone mass, improving bone microarchitecture, and reducing fracture risk in patients with osteoporosis.

Therapeutic Effects of Teriparatide (FORTEO) in Osteoporosis Management

FORTEO (teriparatide) is a PTH 1-34 analog indicated for treating osteoporosis in multiple populations at high fracture risk. Its primary therapeutic effect is stimulating new bone formation through preferential activation of osteoblasts over osteoclasts, resulting in increased bone mass and enhanced bone strength.

In postmenopausal women with osteoporosis, FORTEO significantly reduces the risk of vertebral and nonvertebral fractures by improving trabecular microarchitecture and increasing bone mineral density. Studies demonstrate that the anabolic mechanism manifests as increased skeletal mass and bone formation markers.